You are here

Article info

Article menu
XML
Inflammatory bowel disease
Original article
The safety of vedolizumab for ulcerative colitis and Crohn's disease

Authors

  1. Correspondence to Professor Jean-Frédéric Colombel, Division of Gastroenterology, Inflammatory Bowel Disease Center, Icahn School of Medicine, Mount Sinai Hospital, 17 East 102nd Street, 5th Floor, New York, NY 10029, USA; jean-frederic.colombel{at}mssm.edu
View Full Text

Citation

Colombel J, Sands BE, Rutgeerts P, et al
The safety of vedolizumab for ulcerative colitis and Crohn's disease
Gut 2017;66:839-851.

Publication history

  • Received November 11, 2015
  • Revised January 14, 2016
  • Accepted January 15, 2016
  • First published February 18, 2016.
Online issue publication 
June 15, 2020

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/